Loading stock data…
Femasys Inc. (FEMY)
$2.68-0.30 (-10.07%)
Market ClosedLast close Sep 8
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Femasys Inc. in the Healthcare sector is trading at $2.68 with a market capitalization of $7M. Wall Street consensus targets $14.33 (3 analysts), implying a +434.8% move over the next 12 months. The stock is currently near its 52-week low of $2.02, remaining 69.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +434.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $424,889↓ | $813,387↑ | $729,394↑ | $409,268↑ | $341,264 |
| Gross Profit | $266,283↓ | $510,262↑ | $435,556↑ | $251,097↑ | $223,998 |
| Operating Income | -$4.22M↑ | -$4.62M↓ | -$3.65M↑ | -$3.85M↑ | -$5.46M |
| Net Income | $846,100↑ | -$3.95M↑ | -$4.19M↑ | -$4.59M↑ | -$5.90M |
Peer Comparison
JNJUNHPFE
Fundamentals
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-2.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-163.03%
Volume
Today's trading volume
197,739
Recent News
Femasys Secures FDA Pathway for Non-Surgical Contraceptive
The U.S. Food and Drug Administration (FDA) on Wednesday authorized the modular premarket approval application pathway for FemBloc, a non-surgical permanent birth control technology. Femasys Inc. (NASDAQ:FEMY) announced the regulatory milestone for its investigational contraceptive device. Office-Based Alternative To Surgical Sterilization FemBloc represents a first-of-its-kind permanent birth control option designed specifically for delivery within a standard OB/GYN office setting. During the p
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential
The U.S. Food and Drug Administration accepted Femasys’ modular premarket approval application for FemBloc, an experimental non-surgical permanent birth control technology.
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc
Femasys has received FDA approval to use a modular premarket approval submission process for FemBloc, giving the company a defined regulatory framework as its pivotal U. S.
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.
BC-Most Active Stocks
td class="col-issue">New Era Energy & Digital Inc.